康希诺:13价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)获得药品注册证书

界面
Jun 20

康希诺6月20日公告称,公司已获得国家药品监督管理局下发的13价肺炎球菌多糖结合疫苗(CRM197/破伤风类毒素)《药品注册证书》。该疫苗采用多糖抗原与蛋白载体共价结合的方式,可在2岁以下婴幼儿体内诱导出很高特异性抗体水平,并产生免疫记忆。此外,公司采用双载体技术,可减少与其他疫苗共注射时对免疫原性造成的免疫抑制。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10